当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2011年第32期 > 正文
编号:12150522
131I-间碘苄胍治疗94例恶性嗜铬细胞瘤转移灶25年随访的疗效评价(1)
http://www.100md.com 2011年11月15日 罗琼 罗全勇 朱瑞森 袁志斌 丁颖
第1页

    参见附件(1634KB,2页)。

     [摘要] 目的:观察并总结131I-间碘苄胍(131I-MIBG)治疗恶性嗜铬细胞瘤转移灶的临床疗效。方法:我院1986年1月~2010年1月共收治94例恶性嗜铬细胞瘤转移的患者。按转移瘤大小将其分为三组,三组患者均每隔1~2个月静滴131I-MIBG 80~100 mCi,如果肿瘤组织接受辐照剂量达1 000 cGy/g以上,则每隔3~6个月治疗1次,每次80~100 mCi。结果:大部分患者症状消失,治疗总有效率达73.4%。131I-MIBG对于中小体积的肿瘤的治疗效果较好,与大体积肿瘤疗效比较,差异有统计学意义(χ2=143.19,P<0.05)。每克肿瘤组织接受辐照的剂量与其原始大小有密切关系。每克肿瘤组织接收剂量达1 500~2 000 cGy时,肿瘤可消失或明显缩小。结论:131I-MIBG对恶性嗜铬细胞瘤转移灶具有较好的疗效且副反应较小,不能行手术切除者可首选此方法治疗。

    [关键词] 恶性嗜铬细胞瘤;131I-间碘苄胍;副作用;辐照剂量

    [中图分类号] R817.8 [文献标识码] A [文章编号] 1673-7210(2011)11(b)-029-03

    Efficacy evaluation of 25-year follow-up in 94 cases of m alignant pheochromocytoma with metastases treated by 131I- meta-iodo benzyl guanidine

    LUO Qiong, LUO Quanyong, ZHU Ruisen, YUAN Zhibin, DING Ying

    Department of Nuclear Medicine, Shanghai Jiaotong University Affiliated the Sixth People′s Hospital, Shanghai 200233, China

    [Abstract] Objective: To observe and summarize the therapeutic effects of 131I-MIBG in treatment of m alignant pheochromocytoma with metastases. Methods: 94 patients of m alignant pheochromocytoma with metastases who were treated from January 1986 to January 2010 in our hospital were classified into 3 groups according to their tumor size. Intravenous infusion of 131I-MIBG 80-100 mCi was given every 1-2 months, or every 3-6 months if the absorption dose per gram of tumor was above 1 000 cGy. Results: Clinical symptoms disappeared in most patients after treatment, and the total effective rate was 73.4%. The effects in the small and medium volume groups were better than those in the large volume group (χ2=143.19, P<0.05). The absorption dose of tumor was closely related to its volume. When the absorption dose of tumor attained 1 500-2 000 cGy/g, the tumor was smaller or disappear obviously. Conclusion: 131I-MIBG has certain therapeutic effectiveness and low side effects in treatment of m alignant pheochromocytoma with metastases. Thus, treatment with 131I-MIBG should be the first selection for masses unable surgical resection.

    [Key words] M alignant pheochromocytoma; 131I- meta-iodo benzyl guanidine; Side effect; Absorption dose ......

您现在查看是摘要介绍页,详见PDF附件(1634KB,2页)